Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) is projected to post its Q3 2025 quarterly earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.
Palatin Technologies Trading Down 43.8%
Shares of NYSEAMERICAN PTN opened at $0.10 on Tuesday. The stock has a fifty day simple moving average of $0.38 and a two-hundred day simple moving average of $0.86. Palatin Technologies has a 1-year low of $0.09 and a 1-year high of $2.13. The firm has a market cap of $2.49 million, a price-to-earnings ratio of -0.06 and a beta of 0.87.
Analyst Upgrades and Downgrades
Separately, HC Wainwright decreased their price objective on Palatin Technologies from $17.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, February 13th.
Palatin Technologies Company Profile
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
See Also
- Five stocks we like better than Palatin Technologies
- Stock Average Calculator
- UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- What Ray Dalio’s Latest Moves Tell Investors
- What is Forex and How Does it Work?
- Amazon: Why May Is the Last Month to Get the Stock at a Discount
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
